My ePortfolio Register   

Genetic vs immune strategies in breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.05.17
Views: 870

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Prof André speaks with ecancer at IMPAKT 2017 about establishing genomic triggers and drug targeting against metastatic breast cancer.

He describes acquired and evolved genetic alterations as influences which can separate metastatic behaviour from primary tumours, and the high mutational load of ER metastatic as a possible target for immunotherapy.

Prof André outlines his views on future research, with defining the genomic landscape of early and metastatic breast cancer, and the susceptibilities that follow, as priorities.

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence